Table 4: GvHD and outcome in patients according to ATG administration.
Characteristic (% of patients) | ATG +; n = 11 |
Non-ATG n = 11 |
P |
---|---|---|---|
aGvHD | 55% | 64% | 0.5 |
aGvHD 1-2 grade | 27% | 27% | - |
aGvHD 3-4 grade | 27% | 36% | 0.7 |
cGvHD | 60% | 100% | 0.0001a |
Extended cGvHD Relapse after alloSCT |
22% 27% |
50% 45% |
0.05a 0.1 |
Overall mortality | 54% | 45% | - |
TRM | 27% | 27% | - |
GvHD: Graft-Versus-Host Disease; ATG: Anti-Thymocyte Globulin; aGvHD: Acute Gvhd; cGvHD: Chronic GvHD; alloSCT: Allogeneic Stem Cell Transplantation; TRM: Treatment Related Mortality; aSignificant, P value < 0.05.